UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

Tebboth, Abigail; Ternouth, Andrew; González-Rojas, Núria

doi:10.2147/ceor.s116546

Cited by 14 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other reported side effects included nasopharyngitis, headache, cough, and upper and lower respiratory tract infections; notably, such safety profile was similar to that observed with both placebo and the monocomponents 16,17,21,22. Several cost-effectiveness analyses of all LABA/LAMA FDCs have been published,23–26 consistently showing that different combinations may have a similar cost-effectiveness ratio 27. Another key point is the assessment of the inhaler use.…”

Section: Discussionmentioning

confidence: 68%

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

Lόpez-Campos

Calero-Acuña

Martín

et al. 2017

COPD

View full text Add to dashboard Cite

ObjectiveThe combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic obstructive pulmonary disease (COPD). Here, we systematically review the current knowledge on double bronchodilation for the treatment of COPD, with a specific focus on its efficacy versus placebo and/or monotherapy bronchodilation.MethodsA systematic review of clinical trials investigating LABA/LAMA combination therapies was conducted. Articles were retrieved from PubMed, Embase, and Scopus on June 26, 2016. We specifically selected clinical trials with a randomized controlled or crossover design published in any scientific journal showing the following characteristics: 1) comparison of different LABA/LAMA combinations in a single inhaler for patients with COPD, 2) dose approved in Europe, and 3) focus on efficacy (versus placebo and/or bronchodilator monotherapy) in terms of lung function, respiratory symptoms, or exacerbations.ResultsWe analyzed 26 clinical trials conducted on 24,338 patients. All LABA/LAMA combinations were consistently able to improve lung function compared with both placebo and bronchodilator monotherapy. Improvements in symptoms were also consistent versus placebo, showing some lack of correlation for some clinical end points and combinations versus monotherapy bronchodilation. Albeit being an exploratory end point, exacerbations showed an improvement with LABA/LAMA combinations over placebo in some trials; however, scarce information was available in comparison with bronchodilator monotherapy in most studies.ConclusionOur data show consistent improvements for LABA/LAMA combinations, albeit with some variability (depending on the clinical end point, the specific combination, and the comparison group). Clinicians should be aware that these are average differences. All treatments should be tailored at the individual level to optimize clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 68%

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

Lόpez-Campos

Calero-Acuña

Martín

et al. 2017

COPD

View full text Add to dashboard Cite

show abstract

“…Moreover, the quality‐adjusted life years and costs were identical for Ultibro Breezhaler (indacaterol + glycopyrronium FDC) and Anoro Ellipta (umeclidinium + vilanterol FDC) compared with tiotropium + olodaterol FDC, resulting in identical incremental cost‐effectiveness ratios . Thus, all LABA/LAMAs are cost‐effective options for the treatment of COPD with no clear differences among the class.…”

Section: Clinical Trialsmentioning

confidence: 95%

Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review

Ramadan

Masri²,

Rizk³

2019

Clinical Respiratory J

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is predicted to be one of the leading causes of death worldwide. Pharmacologic treatment options of COPD are bronchodilators, using either long‐acting β2‐agonists (LABAs), or long‐acting muscarinic antagonists (LAMAs), or a combination of two. Anoro Ellipta (umeclidinium + vilanterol) dry powder inhaler, a fixed‐dose combination of LAMA and LABA, was Food and Drug Administration (FDA) approved in 2013 for COPD. The objective of this study is to evaluate the efficacy and safety of once daily umeclidinium/vilanterol (62.5 mcg/25 mcg) in COPD patients, focusing on pharmacodynamic and pharmacokinetic characteristics, efficacy and safety in clinical studies and cost. Literature search was done through PubMed (2004‐2017) using the terms umeclidinium, vilanterol, COPD, LABA and LAMA. Recent and significant clinical trials about the monocomponents and their combination were identified, in addition to reviews, guidelines for COPD, data from manufacturer and FDA product labels. The search was limited to English language studies on human subjects. Clinical data published on the combination of umeclidinium/vilanterol in patients with COPD have shown greater improvements in lung function compared to monotherapies. However, further studies comparing umeclidinium/vilanterol FDC (ANORO) to other LABA/LAMA combinations are needed.

show abstract

“…Фармакоэкономическая оценка препарата Спиолто Респимат при применении у больных с ХОБЛ была проведена в ряде европейских стран [18][19][20]. Во всех представленных исследованиях проводился анализ «затраты -эффективность» с помощью модели Маркова.…”

Section: фармакоэкономическая оценка препарата спиолто респиматunclassified

“…В исследовании, проводимом в Италии, затраты и показатели эффективности дисконтировались по дисконтной ставке 3% [18]; в исследовании, проводимом в Нидерландах, затраты дисконтировались по ставке 4%, показатели эффективности -по ставке 1,5% [19]; в исследовании, проводимом в Великобритании, ставка дисконтирования составила 3,5% как для затрат, так и для показателей эффективности [20].…”

Section: фармакоэкономическая оценка препарата спиолто респиматunclassified

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Зырянов¹,

Галатонова²

2018

Med. sov.

View full text Add to dashboard Cite

В настоящее время существенно изменилась концепция лекарственной терапии пациентов с ХОБЛ. Исследования последних лет убедительно демонстрируют преимущества использования двойной бронхолитической терапии при определенных фенотипах ХОБЛ. Данный обзор посвящен анализу клинической и фармакоэкономической эффективности комбинации тиотропия и олодатерола (Спиолто Респимат). Применение Спиолто Респимата у пациентов с ХОБЛ приводит к улучшению спирометрических показателей, снижению одышки, а также улучшению качества жизни, связанного со здоровьем, в сравнении с плацебо, а также с монотерапией тиотропия бромидом (5 мкг) и олодатеролом (5 мкг). Согласно результатам нескольких проведенных в Европе фармакоэкономических исследований «затраты-полезность», применение препарата Спиолто Респимат по показателям полезности превосходит монотерапию тиотропия бромидом (5 мкг). Помимо этого, было выявлено, что Спиолто Респимат является доминантным в сравнении с препаратом Дуаклир Дженуэйр и комбинацией «тиотропия бромид + салметерол», а также идентичным по показателю «затраты-полезность» с препаратами Ультибро Бризхалер и Аноро Эллипта.

show abstract

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

Cited by 14 publications

References 11 publications

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About